More than one year into Trump 2.0, the FDA’s new leadership has been swept away and even some of the replacements are gone. But the IPO market has surged back from a long and painful dormancy and deals are cooking — particularly in China. Our deep bench of biotech execs assess where the industry is now, where it’s headed and what the biggest threats are on the horizon.
Register to watch on demand
No cost to register, subject to confirmation.
By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.
If you are experiencing problems with your registration, please contact our support team.